Ke Men

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2676152/publications.pdf

Version: 2024-02-01

		430874	454955
36	956	18	30
papers	citations	h-index	g-index
39	39	39	1387
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy. Journal of Controlled Release, 2022, 342, 66-80.	9.9	29
2	Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA. Pharmaceutics, 2022, 14, 162.	4.5	7
3	Dual-RNA controlled delivery system inhibited tumor growth by apoptosis induction and TME activation. Journal of Controlled Release, 2022, 344, 97-112.	9.9	4
4	CXCL13 as a Novel Immune Checkpoint for Regulatory B Cells and Its Role in Tumor Metastasis. Journal of Immunology, 2022, 208, 2425-2435.	0.8	9
5	Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cellular and Molecular Immunology, 2021, 18, 2211-2223.	10.5	46
6	Functionalized DMP-039 Hybrid Nanoparticle as a Novel mRNA Vector for Efficient Cancer Suicide Gene Therapy. International Journal of Nanomedicine, 2021, Volume 16, 5211-5232.	6.7	24
7	Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA. Molecular Pharmaceutics, 2021, 18, 3387-3400.	4.6	13
8	Single Micelle Vectors based on Lipid/Block Copolymer Compositions as mRNA Formulations for Efficient Cancer Immunogene Therapy. Molecular Pharmaceutics, 2021, 18, 4029-4045.	4.6	13
9	Efficient Colorectal Cancer Gene Therapy with IL-15 mRNA Nanoformulation. Molecular Pharmaceutics, 2020, 17, 3378-3391.	4.6	39
10	<p>Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA</p> . International Journal of Nanomedicine, 2020, Volume 15, 9875-9890.	6.7	22
11	Current Progress in Messenger RNA-Based Gene Therapy. Journal of Biomedical Nanotechnology, 2020, 16, 1018-1044.	1.1	16
12	<p>Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy</p> . International Journal of Nanomedicine, 2019, Volume 14, 2733-2751.	6.7	41
13	Induction of neutrophil extracellular traps during tissue injury: Involvement of STING and Tollâ€like receptor 9 pathways. Cell Proliferation, 2019, 52, e12579.	5.3	60
14	Recent Advances in Therapeutic Genome Editing in China. Human Gene Therapy, 2018, 29, 136-145.	2.7	5
15	Current Status of Nonviral Vectors for Gene Therapy in China. Human Gene Therapy, 2018, 29, 110-120.	2.7	16
16	A Vesicular Stomatitis Virusâ€Inspired DNA Nanocomplex for Ovarian Cancer Therapy. Advanced Science, 2018, 5, 1700263.	11.2	16
17	Delivery of modified mRNA encoding vesicular stomatitis virus matrix protein for colon cancer gene therapy. RSC Advances, 2018, 8, 12104-12115.	3.6	12
18	Local and Systemic Delivery of Interleukin-12 Gene by Cationic Micelles for Cancer Immunogene Therapy. Journal of Biomedical Nanotechnology, 2018, 14, 1719-1730.	1.1	18

#	Article	IF	CITATIONS
19	Modified Fe3O4 Magnetic Nanoparticle Delivery of CpG Inhibits Tumor Growth and Spontaneous Pulmonary Metastases to Enhance Immunotherapy. Nanoscale Research Letters, 2018, 13, 240.	5.7	34
20	Negative regulation of cationic nanoparticle-induced inflammatory toxicity through the increased production of prostaglandin E2 via mitochondrial DNA-activated Ly6C ⁺ monocytes. Theranostics, 2018, 8, 3138-3152.	10.0	25
21	Delivery of a Modified mRNA Encoding IL-22 Binding Protein (IL-22BP) for Colon Cancer Gene Therapy. Journal of Biomedical Nanotechnology, 2018, 14, 1239-1251.	1.1	44
22	Delivery of interleukin-22 binding protein (IL-22BP) gene by cationic micelle for colon cancer gene therapy. RSC Advances, 2018, 8, 16537-16548.	3.6	10
23	Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. Science China Life Sciences, 2017, 60, 458-467.	4.9	40
24	CRISPR/Cas9-mediated correction of human genetic disease. Science China Life Sciences, 2017, 60, 447-457.	4.9	34
25	The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth <i>in vivo</i> . Oncotarget, 2017, 8, 45951-45964.	1.8	18
26	Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene. International Journal of Nanomedicine, 2016, 11, 501.	6.7	7
27	Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long-lasting and balanced immune responses. Molecular Medicine Reports, 2016, 13, 915-924.	2.4	6
28	Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening. Molecular BioSystems, 2016, 12, 1540-1551.	2.9	22
29	Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis. International Journal of Nanomedicine, 2015, 10, 5205.	6.7	30
30	Treating colon cancer with a suicide gene delivered by self-assembled cationic MPEG–PCL micelles. Nanoscale, 2012, 4, 2400.	5.6	36
31	Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system. Nanoscale, 2012, 4, 6425.	5.6	62
32	PCL/PEG Copolymeric Nanoparticles: Potential Nanoplatforms for Anticancer Agent Delivery. Current Drug Targets, 2011, 12, 1131-1150.	2.1	87
33	Preparation of Magnetic Microspheres Based on Poly(<1>îµ 1 -Caprolactone)-Poly(Ethylene) Tj ETQq1 I Journal of Biomedical Nanotechnology, 2010, 6, 287-292.	l 0.78431 1.1	4 rgBT /Ove 6
34	A Novel Drug and Gene Co-Delivery System Based on Poly(<l>ε</l> -caprolactone)-Poly(ethylene) Tj ETC Nanoscience and Nanotechnology, 2010, 10, 7958-7964.	0.9 0 0 o rgl	BT /Overloci 17
35	Efficient Inhibition of C-26 Colon Carcinoma by VSVMP Gene Delivered by Biodegradable Cationic Nanogel Derived from Polyethyleneimine. ACS Nano, 2010, 4, 5573-5584.	14.6	79
36	Local and Systemic Delivery of the BimS Gene Nano-Complex for Efficient Oral Squamous Cell Carcinoma Therapy. International Journal of Nanomedicine, 0, Volume 17, 2925-2941.	6.7	5